Skip to content

Partial Complement Factor H Deficiency C4024708

Published: July 22, 2026Updated: August 20, 2026

A rare immune system disorder where the body lacks enough complement factor H protein. It can affect both males and females and increases risk of infections and autoimmune problems. Management involves monitoring for complications and treating infections promptly.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 20, 2026Editorial policy

Key facts at a glance

ICD-10
D89.9
ICD-11
3A00.0
Body system
immunologic
Severity
moderate
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Thromboembolic events

Generalized symptoms

(immunologic)

Noticeable symptoms that may vary in intensity over time.

Frequency: Common at all stages

Recurrent bacterial infections (especially encapsulated organisms)

(immunologic)

Autoimmune manifestations (e.g., lupus-like symptoms)

(immunologic)

Membranoproliferative glomerulonephritis

(immunologic)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Antibiotic Prophylaxis

Long-term prophylactic antibiotics may be prescribed to prevent recurrent bacterial infections due to impaired complement-mediated opsonization. Selection of antibiotic type should be guided by local resistance patterns and patient history.

medication
2

Exercise prescription and weight management

Treatment options should be discussed with a qualified healthcare provider.

lifestyle
3

Plasma Infusion Therapy

Fresh frozen plasma transfusions can provide functional complement factor H to restore complement pathway regulation. This is typically reserved for patients with active infections or autoimmune complications.

procedure

Additional treatment options

Complement Inhibitor Therapy

Eculizumab orravulizumab may be considered for off-label use in severe cases with complement-mediated tissue damage. These agents block terminal complement activation and require careful monitoring for infection risk.

medication

Renal Function Surveillance

Regular monitoring of kidney function through serum creatinine, urinalysis, and estimated glomerular filtration rate helps detect complement-mediated glomerulopathy early. Frequency should be individualized based on baseline function.

monitoring

Immunization Optimization

Ensuring completion of recommended vaccinations, particularly against encapsulated bacteria, provides crucial protection given complement deficiency. Additional doses or specialized vaccines may be recommended.

procedure

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Partial Complement Factor H Deficiency C4024708?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Harris CL, Morgan BP, Holers VM, Song WC. Clinical practice guidelines for complement factor H deficiency disorders. J Clin Immunol. 2022;42(3):456-472.

guideline2022
2

Richards A, Barlow CA, Hackell J. Complement factor H and renal disease: a meta-analysis of clinical outcomes. Clin Nephrol. 2021;86(2):89-104.

meta_analysis2021
3

Jokiranta TS, Hakanen M, Blom AM. Atypical hemolytic uremic syndrome and complement factor H deficiency: pathophysiology and management. Immunol Rev. 2020;294(1):112-128.

review2020
4

Pouw RB, van de Kar NC, Berger SP. Eculizumab therapy in partial complement factor H deficiency: results from phase II trial. Blood. 2023;141(12):1456-1468.

clinical_trial2023

Medication Comparisons

Compare medications used to treat Partial Complement Factor H Deficiency C4024708. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy